Efficacy safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus

摘要

AimThe efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus therapy for subjects with gestational diabetes mellitus (GDM).